


Parkinson disease with mild cognitive impairment: Domain-specific cognitive complaints predict dementia

Carmen Gasca-Salas¹  | Sarah Duff-Canning² | Melissa J. Armstrong³ | Paul J. Eslinger⁴ | Ruth B. Schneider⁵ | Nancy Kennedy⁶ | Kelvin L. Chou⁷ | Carol Persad⁸ | Irene Litvan⁹ | Sandra Weintraub^{7,10} | Connie Marras²

¹Centre for Integrative Neuroscience AC, HM Puerta del Sur, CEU San Pablo University, Madrid, Spain

²The Morton Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada

³Department of Neurology, University of Florida College of Medicine, Gainesville, FL, USA

⁴Department of Neurology, Penn State Hershey Medical Center, Hershey, PA, USA

⁵Department of Neurology, University of Rochester, Rochester, NY, USA

⁶Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

⁷Department of Neurology, University of Michigan, Ann Arbor, MI, USA

⁸Neuropsychology Program, Department of Psychiatry, Michigan Medicine and the University Center for Language and Literacy, Mary A. Rackham Institute, University of Michigan, Ann Arbor, MI, USA

⁹UC San Diego Department of Neurosciences, Parkinson and Other Movement Disorders Center, San Diego, CA, USA

¹⁰Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Correspondence

Carmen Gasca-Salas, Centro Integral en Neurociencias (CINAC), University Hospital HM Puerta del Sur, CEU-San Pablo University, Móstoles, Madrid, Spain.
Email: cgasca.hmcinac@hmhospitales.com

Funding information

Michael J Foundation for Parkinson's Research; The Canadian Institutes of Health Research.

Background: The presence of subjective cognitive complaints (SCC) as a predictor of cognitive impairment in Parkinson's disease (PD) has shown conflicting results. Most previous studies only assessed complaints in the memory domain. We investigate the association of SCCs across cognitive domains with development of mild cognitive impairment (PD-MCI) and dementia (PDD) in PD and to assess agreement between SCCs and objective cognitive impairments in this population.

Methods: This is a retrospective analysis of a prospective cohort study. Participants were enrolled at six North-American movement disorders centers. They underwent neuropsychological and non-cognitive clinical evaluations, including the modified Neurobehavioral Inventory to elicit SCC (rated by each patient and independently by their close contact (CC)). Associations between SCCs and development of future cognitive impairment were assessed. Agreement between SCCs and objective impairment within the same domain was also calculated.

Results: Of 138 included PD patients, 42% fulfilled criteria for PD-MCI. None of the NBI items predicted development of cognitive impairment after one and two years in PD with normal cognition. In PD-MCI patients, SCCs related to attention predicted dementia at year one. CC ratings of SCCs related to memory and language problems predicted PDD in PD-MCI patients. According to CC reported patients' complaints,

there was a significant agreement between SCCs and objective cognitive test scores on attention.

Conclusions: Eliciting SCCs including cognitive domains other than memory is crucial for a complete evaluation, including both patient and CC report. Memory, language, and especially attention SCCs in PD-MCI may predict progression to dementia.

KEYWORDS

cognitive complaint, dementia, mild cognitive impairment, Parkinson's disease

1 | INTRODUCTION

Mild cognitive impairment (MCI) and dementia are well-recognized entities in Parkinson's disease (PD). MCI is characterized by cognitive deficits with no effect on daily functioning, but a subjective cognitive complaint (SCC) is needed for the diagnosis.¹ This entity represents an intermediate state between normal cognition and dementia. Its frequency ranges from 20% to 65% among PD patients.^{2,3}

In the general aging population as well as in PD,⁴ SCCs are very common. Increasing evidence links subjective decline with an increased risk for future cognitive decline and Alzheimer's disease (AD).⁵⁻⁷ Therefore, in non-cognitively impaired subjects, SCCs may reflect subtle cognitive deficits. However, the presence of cognitive complaints as a predictor of cognitive impairment in PD has shown conflicting results. Erro,⁸ Hong⁹ and Galtier¹⁰ found that the presence of cognitive complaints predicted PD-MCI after 2, 2.5, and 7.5 years of follow-up, respectively. Conversely, we recently found no association between SCC and cognitive impairment at the time of the evaluation or cognitive decline after one and two years of follow-up in individuals with PD without dementia (PD with normal cognition [PD-CN] and PD-MCI).¹¹ These conflicting findings might correspond to the methodology used. The first three studies based the presence of cognitive complaints only on the existence of memory complaints and used PD-MCI criteria level I, which provide less diagnostic certainty than level II criteria. In our previous study, we used several methods of eliciting cognitive complaints, covering cognitive complaints in attention, memory, executive function, language and non-verbal skills, and applied PD-MCI level II criteria.¹¹ According to previous studies, memory complaints may be particularly predictive of future cognitive decline in PD. Since cognitive impairment in PD is heterogeneous and may involve different cognitive domains, it is important to understand the role of complaints in other domains as a potential marker of cognitive decline. In addition, specific cognitive complaints that predict Parkinson's disease dementia (PDD) in PD-MCI have not been evaluated and might represent a marker of progression to dementia in this population.

Gradual cognitive decline is required as a part of the diagnosis of PD-MCI and can be inferred from SCCs reported by either the patient or the informant or may be observed by the physician. Copeland et al showed a moderate level of agreement in PD-MCI patients' and care partners' subjective reports for memory, language, visuospatial

skills, and executive functioning, but not for attention.¹² However, we recently found in a sample of persons with PD without dementia (both PD-CN and PD-MCI) that there was statistically significant agreement between the CC report of subjective complaints and the patient-reported measures but kappa values were low (<0.2).¹¹ Therefore, for cognitive assessment in PD, a CC interview about patient cognitive changes might be an important adjunct to the patient's report. In the current study, we investigated the association between specific cognitive complaints and the concurrent presence of PD-MCI. Second, we investigated the association between specific cognitive complaints and the development of PD-MCI and PDD after one and two years of follow-up. Third, we measured the agreement (according to presence or absence) among specific cognitive complaints and cognitive domain impairments on neuropsychological testing.

2 | METHODS

2.1 | Subjects

A non-consecutive, convenience sample of English-speaking persons with PD without dementia were enrolled at six North American tertiary care movement disorders centers for a prospective study of PD-MCI screening measures. This is a retrospective analysis of the longitudinal cohort study. The recruitment period was from December 2008 to June 2011. Other inclusion and exclusion criteria have been reported previously.¹³ Written informed consent was obtained from all study participants and participating informed contacts (defined as contact at least twice weekly) before formal screening and study visits. PD patients received an annual clinical evaluation followed 1-3 weeks later by formal neuropsychological testing performed blinded to clinical results.

The Ethics Committee of each institution approved the study.

2.2 | Data collection

Evaluation of non-cognitive PD signs and symptoms and neuropsychological testing was performed at a similar time of day and participants were evaluated in the ON state. PD patients with significant

TABLE 1 Baseline characteristics

	Baseline	1 year	2 years
Total no.	138	121	109
Age, y (median, range)	71.06 (5.44)	71.02 (5.37)	70.82 (5.22)
Gender, % male	67	68	67
Education, y (median, range)	15.82 (2.52)	15.92 (2.42)	16.01 (2.43)
Estimated premorbid IQ	113.20 (9.01)	113.48 (9.03)	114.41 (8.38)
Time since diagnosis, y (median, range)	4 (4.59)	4.77 (4.02)	4.76 (4.04)
Total MDS-UPDRS (median, range)	43 (16.83)	45 (16.59)	44 (15.90)
MDS-UPDRS-III (median, range)	26.80 (11.28)	30 (11.47)	26.50(11.10)
Total LEU, mg (median, range)	414 (358.38)	500 (336.35)	600 (342.19)
MoCA total score (median, range)	25.2 (2.93)	26 (2.90)	26 (2.77)
SCOPA-Cog (median, range)	27.50 (4.84)	28 (4.74)	29 (4.81)
MMSE (median, range)	28.30 (1.83)	29(1.81)	29 (1.67)
PD-MCI			
Relative to estimated premorbid IQ ^a (N,%)	110 (79.7)	94 (78)	69(66)
Relative to population norms ^b (N,%)	57 (41.30)	40 (28.8)	31 (22.33)
Parkinson disease dementia ^c (N%)	-	11 (9.09)	8 (7.3)
Geriatric Depression scale (median, range)	1.30 (1.31)	1 (1.26)	2(1.30)
Cognitive complaint measures			
NBI-Subject # with no complaint	55 (39.80)	38 (31.93)	28 (26.92)
NBI-Subject # with one complaint	25 (18.10)	27 (22.68)	24 (23.07)
NBI-Subject # ≥2 complaint	58 (42)	56 (47.05)	52 (50)
NBI-Close Contact # with no complaint	97	76	72
NBI-Close Contact # with one complaint	24	20	7
NBI-Close Contact # ≥2 complaint	17	24	25
General complaint question (N answering yes, %)	54 (39)	51 (46)	51 (49)
UPDRS 1.1 (N with score > 0, %)	45 (32)	51 (42)	40 (38)

Abbreviations: LEU, levodopa equivalent units; MCI, mild cognitive impairment; MDS-UPDRS-III, Movement Disorders Society United Parkinson's Disease Rating Scale, part 3; MMSE, Mini-Mental State Examination.; MoCA, Montreal Cognitive Assessment; SCOPA-Cog, Scale for Outcomes in Parkinson's Disease-Cognition.

^aImpairment on neuropsychological tests defined as 1.5 SD below expected performance based on Wechsler Test of Adult Reading.

^bImpairment on neuropsychological tests defined as 1.5 SD below population norms.

^cDiagnosis of Parkinson's disease dementia is when a person is originally diagnosed with Parkinson's based on Queen Square Brain Bank criteria and followed by dementia symptoms that appear a year or more later.

depression (a score of 5 or greater) according to the 15-item geriatric depression scale (GDS-15) were excluded ($n = 4$). SCCs were elicited using a modified Neurobehavioral Inventory (NBI) (Professional Resources and Technologies, Westtown, PA, Appendix S1), a list of 19 cognitively based problems with everyday life. Complaints are grouped in domains related to attention (trouble sustaining attention, trouble listening well, easily distracted), executive function (trouble finishing tasks, trouble sequencing steps, poorly organized/unable to plan), memory (forgetting recent events, forgetting remote events, forgetting names, forgetting appointments, forgetting medications, forgetting where objects are placed), language (trouble naming, rambling, trouble understanding conversations, trouble understanding what is read), and non-verbal skills (getting lost, finding multiple step activities confusing, dressing confusion). This

was administered to patients and close contacts (CC) separately. Questions aimed to identify whether a problem was present. The problem was considered as present only in the case of being new and not present the subject's whole life.^{11,13,14}

Each new problem is given a score of one point. Patients free of cognitive complaints would have a score of 0, and the higher score the more cognitive complaints. We also used other methods for eliciting SCC,¹¹ but we use the NBI for the current analysis as it assesses SCC across specific cognitive domains.

Impairment of functional independence related to cognitive problems was assessed by the Disability Assessment for Dementia¹⁵ administered to the CC. When one or more items of the questionnaire were impaired due to cognition, the patient was classified as having dementia. This was modified to specify

whether or not impairment related to cognitive problems or to physical limitations and only impairment secondary to cognitive problems was accepted as evidence of functional impairment. The Movement Disorders Society United Parkinson's Disease Rating Scale (MDS-UPDRS) was administered by a movement disorders neurologist.

2.3 | Diagnosis of cognitive impairment

Diagnosis of PD-MCI was defined as a score of 1.5 SD or more below the normative mean on at least two neuropsychological tests to align with the MDS Task Force Level II criteria.¹⁶ Since we aimed to evaluate the prognostic value of SCCs, the MCI diagnosis was made solely on the basis of the neuropsychological findings, regardless of the presence of subjective cognitive complaints. PDD was diagnosed according to MDS criteria. This was defined as an impairment in at least two cognitive domains that represents a decline from premorbid level and is severe enough to impair functional independence.¹⁷

2.4 | Neuropsychological assessment

The neuropsychological assessment included two tests from five different cognitive domains. (a) Attention: the Delis Kaplan Executive Function System (DKEFS) Color Word Interference Color Naming test¹⁸ and the Wechsler Memory Scale-III letter-number sequencing test,¹⁹ (b) Language: the DKEFS Verbal Fluency Category Fluency test^{18,20} and the 30-item Boston Naming Test²¹; (c) Executive function: the Trail Making Test B minus A²² and the Visual Verbal Test abbreviated 10-item version,²³ (d) Memory: the Rey Complex Figure

Test and Recognition Trial (RCFT) Delayed Recall²⁴ and the California Verbal Learning Test-II Long Delay Free Recall test, and²⁵ (e) visuospatial function: the Benton Judgment of Line Orientation test²⁶ and the Copy Trial of the RCFT²⁶

2.5 | Data analysis

Our analysis was divided in three parts.

First, in order to assess the association between each cognitive complaint and PD-MCI diagnosis at baseline, we used a chi-square test and quantified the association using odds ratios (OR).

Second, using the same statistical test, we studied the association between specific cognitive complaints at baseline and development of either PD-MCI or PDD in patients who were PD-CN at baseline, and PDD in PD-MCI after 1 and 2 years of follow-up. A logistic regression analysis was performed for significant associations between specific cognitive complaints and prediction of PD-MCI or PDD (after adjustment for multiple comparisons). Potential confounders for cognitive impairment (age, education and sex) were included.

Third, we measured the agreement among objective impairment in specific cognitive domains and specific cognitive complaints (according to presence or absence) using a kappa coefficient (*k*). An impairment of a cognitive domain was considered present when Z-score of at least one of the two test values was at least 1.5 SD or more below the normative mean.

Within each of the three parts of this study, we defined the threshold for statistical significance as 0.05 divided by the number of statistical tests performed. This was 0.0026 for the first and second analysis, whereas in the third analysis, the threshold was different among the cognitive domains due to the different number of SCC questions related to each domain (memory = 0.01, attention = 0.017, executive function = 0.017, language = 0.0125, non-verbal = 0.017).

Statistical analyses were performed with SPSS 20 software (IBM).

3 | RESULTS

3.1 | Demographics

Data on 138 patients were included at baseline. At year 1, 121 patients were assessed for follow-up and, at year 2, 109. The median age at baseline was 71 (range 60-84), and median time from diagnosis was four (range 1-29) years. Fifty-seven (41%) patients met criteria for diagnosis of PD-MCI at baseline since they had impairment on two or more tests of the core neuropsychological test battery. Demographic, motor, and other clinical features of the patients at baseline and follow-up are listed in Table 1.

After one year of follow-up, 18 (25.71%) PD-CN patients converted to PD-MCI or dementia and 9 (17.65%) PD-MCI patients converted to PDD. At year 2, 13 (23.61%) PD-CN baseline patients




FIGURE 1 Graphical summary of conversion and reversion rates at year and 2 of follow-up according to PD cognitive diagnosis at baseline. BL = baseline, PD-CN = Parkinson's disease with normal cognition, PD-MCI = Parkinson's disease with mild cognitive impairment, PDD = Parkinson's disease with dementia. Y1 = year 1, Y2 = year 2

TABLE 2 Association between Cognitive Complaint in PD with Mild cognitive Impairment (PD-MCI) at baseline and conversion to dementia at year 1

NBI item	Patient			Close contact		
	PD-MCI stable (n = 42) [N (%)]	PD-MCI converters (n = 9) [N (%)]	P value and OR (2 × 2)	PD-MCI stable (n = 42) [N (%)]	PD-MCI (n = 9) converters [N (%)]	P value and OR (2 × 2)
Memory						
1. Forgetting recent events	8 (19%)	2 (22%)	.828 (1.21)	4 (9.5%)	4 (44%)	.009 (7.6)
2. Forgetting remote events	6 (14.3%)	2 (22%)	.552 (1.71)	5 (11.9%)	3 (33%)	.109 (3.7)
3. Forgetting names	8 (19%)	4 (44%)	.103 (3.40)	7 (16.7%)	2 (22%)	.692 (1.43)
4. Forgetting appointments	0 (0%)	0 (0%)	NA	2 (4.8%)	3 (33%)	.009 (10.00)
5. Forgetting medications	2 (4.8%)	2 (22%)	.077 (5.71)	2 (4.8%)	4 (44%)	.001(16.00)
6. Forgetting where objects are placed	5 (11.9%)	2 (22%)	.414 (2.11)	8 (19%)	6 (67%)	.004 (8.5)
Attention						
1. Trouble sustaining attention	4 (9.5%)	0 (0%)	.335 (0.91)	4 (9.5%)	4 (44%)	.009 (7.6)
2. Trouble listening	2 (4.8%)	4 (44%)	.001 (16.00)	5 (11.9%)	1 (11%)	.947 (0.93)
3. Well easily distracted	3 (7.1%)	0 (0%)	.409 (0.93)	5 (11.9%)	1 (11%)	.947 (0.93)
Executive						
1. Trouble finishing tasks	5 (11.9%)	2 (22%)	.414 (2.11)	3 (7.1%)	2 (22%)	.167 (3.71)
2. Trouble sequencing steps	1 (2.4%)	1 (11%)	.221 (5.13)	0 (0%)	0 (0%)	NA
3. Poorly organized/unable to plan	2 (4.8%)	0 (0%)	.504 (0.95)	3 (7.1%)	3 (33%)	.027 (6.50)
Language						
1. Trouble naming	7 (16.7%)	3 (33%)	.253 (2.50)	4 (9.5%)	4 (44%)	.009 (7.60)
2. Rambling	3 (7.1%)	1 (11%)	.688 (1.63)	4 (9.5%)	1 (11%)	.884 (1.19)
3. Trouble understanding conversations	1 (2.4%)	0 (0%)	.64 (0.98)	1(2.4%)	3 (33%)	.002 (20.50)
4. Trouble understanding what is read	3 (7.1%)	2 (22%)	.167 (3.71)	0 (0%)	2 (22%)	.002 (1.290)
Non-verbal						
1. Getting lost	0 (0%)	0 (0%)	NA	0 (0%)	0 (0%)	NA
2. Finding multiple step activities confusing	3 (33.3%)	0 (0%)	.409 (0.93)	2 (4.8%)	2 (22%)	.077 (5.71)
3. Dressing confusion	0 (0%)	0 (0%)	NA	0 (0%)	1 (11%)	.029 (1.13)

Note: The threshold for statistical significant considering correction for multiple comparisons = 0.0026. Statistically significant results are shown in bold type. Statistically significant results before multiple comparisons correction are shown in italics.

Abbreviation: NA, non-admitted.

converted to PD-MCI or PDD and 10 (22.22%) PD-MCI patients converted to PDD (Figure 1).

The CC included spouses in the majority of cases (71%) being less common, children (15%), friend/neighbor (9%) and sibling, partner/girlfriend (2% each). In addition, isolated cases of daughter-in-law and roommate were included as informants.

- Association between Cognitive Complaint and PD-MCI diagnosis at baseline.

There were no specific cognitive complaints significantly associated with PD-MCI after adjustment for multiple comparisons. Before adjustment for multiple comparisons, several questions were associated with cognitive impairment (Table S1).

- Association between Cognitive Complaint in PD-CN at baseline and progression to MCI or dementia at year 1 and 2.

None of the NBI items predicted development of cognitive impairment after 1 and 2 years in individuals who were PD-CN at baseline. Tables S2 and S3 show which of the questions predicted cognitive impairment in this group of patients before multiple comparisons adjustment.

- Association between Cognitive Complaint in PD-MCI at baseline and progression to PDD at year 1 and 2.

In individuals determined to have PD-MCI at baseline, patient-reported inattentiveness at year 1 was associated with

TABLE 3 Association between Cognitive Complaint in PD with Mild cognitive Impairment (PD-MCI) at baseline and conversion to dementia at year 2

NBI item	Patient			Close contact		
	PD-MCI stable (n = 35) [N (%)]	PD-MCI converters (n = 10) [N (%)]	P value and OR (2 × 2)	PD-MCI stable (n = 35) [N (%)]	PD-MCI converters (n = 10) [N (%)]	P value and OR (2 × 2)
Memory						
1. Forgetting recent events	8 (22.3%)	2 (20%)	.848 (0.84)	3 (8.6%)	4 (40%)	.016 (7.1)
2. Forgetting remote events	5 (14.3%)	2 (20%)	.660 (1.50)	4 (11.4%)	3 (30%)	.153 (3.32)
3. Forgetting names	9 (25.7%)	3 (30%)	.787 (1.24)	6 (17.1%)	2 (20%)	.835 (1.21)
4. Forgetting appointments	0 (0%)	0 (0%)	NA	1 (2.9%)	3 (30%)	.008 (14.57)
5. Forgetting medications	1 (2.9%)	3 (30%)	.008 (14.57)	1 (2.9%)	4 (40%)	.001 (22.68)
6. Forgetting where objects are placed	5 (14.3%)	2 (20%)	.660 (1.50)	8 (22.3%)	6 (60%)	.025 (5.06)
Attention						
1. Trouble sustaining attention	4 (11.4%)	0 (0%)	.263 (0.89)	4 (11.4%)	4 (40%)	.037 (5.17)
2. Trouble listening	2 (5.7%)	3 (30%)	.031 (7.07)	4 (11.4%)	1 (10%)	.899 (0.86)
3. Well easily distracted	1 (2.9%)	1 (10%)	.334 (3.78)	3 (8.6%)	2 (20%)	.899 (0.86)
Executive						
1. Trouble finishing tasks	3 (8.6%)	3 (30%)	.079 (4.57)	3 (8.6%)	2 (20%)	.310 (2.67)
2. Trouble sequencing steps	1 (2.9%)	1 (10%)	.334 (3.78)	0 (0%)	0 (0%)	NA
3. Poorly organized/unable to plan	2 (5.7%)	0 (0%)	.439 (0.94)	2 (5.7%)	3 (30%)	.031 (7.07)
Language						
1. Trouble naming	7 (20%)	2 (20%)	1 (1)	4 (11.4%)	4 (40%)	.037 (5.2)
2. Rambling	2 (5.7%)	2 (20%)	.162 (4.13)	2 (5.7%)	1 (10%)	.632 (1.83)
3. Trouble understanding conversations	0 (0%)	0(0%)	NA	1(2.9%)	3 (30%)	.008 (14.57)
4. Trouble understanding what is read	3 (8.6%)	2 (20%)	.310 (0.27)	0 (0%)	2 (20%)	.007 (1.25)
Non-verbal						
1. Getting lost	0 (0%)	0 (0%)	NA	0 (0%)	0 (0%)	NA
2. Finding multiple step activities confusing	2 (5.7%)	0 (0%)	.439 (0.94)	1 (2.9%)	2 (20%)	.055 (8.5)
3. Dressing confusion	0(0%)	0(0%)	NA	0(0%)	1 (10%)	.058 (1.11)

Note: The threshold for statistical significant considering correction for multiple comparisons = 0.0026. Statistically significant results are shown in bold type. Statistically significant results before multiple comparisons correction are shown in italics.

Abbreviation: NA, non-admitted.

development of PDD at year 1 ($P = .001$, $OR = 16$; Table 2), after adjusting for potential confounders there was a trend towards significance ($P = .051$, $OR = 2.46$). No patient-reported SCC at baseline was associated with development of PDD at year 2 (Table 3). Close contact-reported SCC about forgetting medications, difficulty understanding conversations, and difficulty understanding what is read was associated with PDD at year 1 ($P = .001$, $OR = 16$; $P = .002$, $OR = 20.5$, and $P = .002$, $OR = 1.29$, respectively; Table 2). The two first SCC remained significant after adjusting for confounders: forgetting medications ($OR = 23.26$; $P = .003$) and difficulty understanding conversations ($OR = 38.46$; $P = .01$). At year 2 CC reported SCC for forgetting medications was also associated with PDD ($P = .001$, $OR = 2.68$, Table 3), this was also significant after adjusting for confounders ($OR = 66.67$, $P = .003$).

- Agreement between subjective complaints and objective cognitive impairments within the same domain.

In PD-MCI patients, there was no statistically significant agreement between subjective complaints and objective cognitive impairments within the same domain. See Table 4 for significant agreement before adjusting for multiple comparisons. According to CC reported patients' complaints, agreement for the presence of a cognitive complaint occurred more frequently than by chance between attention questions related to trouble listening well and easily distracted and attention domain impairment (both comparisons $P = .002$, $\kappa = 0.387$, fair agreement).²⁷ Before multiple comparisons correction, there was also significant agreement between domain-specific cognitive complaints and objective cognitive test scores (see Table 5).

TABLE 4 Baseline Agreement (Kappa value)^a between objective deficits and subjective reports in PD-MCI according to patient's report

	Forgetting recent events		Forgetting remote events		Forgetting names		Forgetting appointments		Forgetting medications		Forgetting where objects are placed	
	P value	Kappa	P value	Kappa	P value	Kappa	P value	Kappa	P value	Kappa	P value	Kappa
(a) Memory questions												
Memory	0.028	.786	0.028	.786	0.166	0.132	0	0.067	0.317	0.133	.183	
Attention	0.324	.014	0.099	.456	0.694	.052	0	-0.115	.310	0.125	.345	
Executive	0.006	.917	0.006	.917	0.027	.684	0	0.035	.310	-0.004	.951	
Language	0.008	.951	0.008	.951	-0.139	.288	0	-0.111	.452	-0.091	.49	
Visuospatial	-0.169	.018	-0.006	.936	-0.02	.01	0	0.052	.215	-0.020	.771	
Trouble sustaining attention												
		P value		P value		P value		P value		P value		P value
(b) Attention questions												
Memory	-0.141	.035	0.135	.093	0.102	.080						
Attention	0.183	.107	0.115	.357	-0.090	.384						
Executive	0.035	.310	0.055	.205	-0.019	.527						
Language	0.047	.684	-0.08	.952	-0.088	.412						
Visuospatial	-0.047	.265	0.03	.57	0.039	.288						
Trouble finishing tasks												
		P value		P value		P value		P value		P value		P value
(c) Executive function questions												
Memory	-0.108	.208	-0.001	.98	-0.001	.98						
Attention	0.346	.007	0.1	.263	0.1	.352						
Executive	0.065	.167	0.017	.481	-0.027	.263						
Language	-0.031	.809	-0.062	.507	-0.062	.507						
Visuospatial	-0.008	.885	-0.023	.439	-0.023	.439						
Trouble naming												
		P value		P value		P value		P value		P value		P value
(d) Language questions												
Memory	0.236	.022	0.101	.173	0.068	.157	0.100	.246				
Attention	-0.125	.340	0.005	.967	-0.063	.481	0.085	.507				
Executive	-0.045	.456	-0.002	.967	0.017	.481	0.065	.167				
Language	-0.108	.412	0.019	.88	-0.062	.507	-0.031	.809				
Visuospatial	-0.060	.400	-0.016	.737	0.026	.390	-0.060	.289				

(Continues)

TABLE 4 (Continued)

	Getting lost		Finding multiple step activities confusing		Dressing confusion	
	P value		P value		P value	
(e) Non-verbal questions						
Memory	0	NA	0.033	0	.574	NA
Attention	0	NA	0.066	0	.527	NA
Executive	0	NA	0.026	0	.384	NA
Language	0	NA	-0.088	0	.412	NA
Visuospatial	0	NA	0.039	0	.288	NA

Note: NA, Non-admitted (no patients complained about it).

^aAgreement according to presence or absence of any complaint (kappa value).

4 | DISCUSSION

Considering the contradictory results of previous reports about the relationship between cognitive complaints and development of objective cognitive impairment in PD and the limited examination of complaints outside the memory domain, we aimed to find whether SCCs beyond memory complaints could predict cognitive decline in PD. For this purpose, we used the NBI questionnaire that allows for the description of specific domains of complaint and is very clear for tabulating the type and number of items. This inventory has been used reliably in multicenter patient samples and related analyses.^{11,13,14}

Our main finding was that specific SCCs are associated with dementia in patients with PD-MCI. Regarding patients' complaints, PD-MCI subjects who considered themselves inattentive had a higher risk of developing PDD after one year ($P = .051$). However, according to CC related to patients, language difficulties (understanding conversations) and memory complaints about forgetting to take their medications predicted decline after one year of follow-up. Interestingly, attention deficits are very prominent in PDD; therefore, it is plausible that attention complaints could be an early sign of this typical deficit prior to progression to dementia.²⁸ Language comprehension complaints were only reported by the CC. Even though processing and comprehension of complex grammar and syntax appear in PD, they are not usually evaluated in the neuropsychological assessment.²⁹ Also, there is usually lack of awareness of language difficulties.^{30,31} The third complaint that predicted progression to dementia was forgetting to take one's medications, also reported by the CC and not by the patient. This specific memory complaint heralds loss of personal autonomy that defines the diagnosis of dementia. The Pill Questionnaire³² has been proposed as a way to probe this function and is rated by direct observation of medication reporting by the interviewer and if necessary corroborated by a caregiver. Even though this questionnaire is neither sensitive nor specific as the sole screening tool for PD-MCI or as a measure of functional impairments,³² inaccurate medication reporting by the CC in the presence of a diagnosis of PD-MCI has been shown to predict development of dementia in the next year.^{33,34} This is in keeping with our results.

In the second part of the study, we investigated the agreement between subjective and objective cognitive impairment in PD-MCI. Interestingly, we found a fair agreement between attention SCCs (trouble listening well and easily distracted) according to CC complaints and attention domain impairment, but not with patients' complaints. As PD-MCI patients may be unaware of their cognitive deficits^{30,31} and there is no agreement in attention complaints between patients and CC reports,^{12,13} we emphasize that it is important to elicit SCCs from patients and CC. Unexpectedly, we found slight agreement between patients' complaints about forgetting names and visuospatial impairment and no statistically significant agreement for the rest of the variables. Even though these measures seem to be independent, difficulty naming along with visuospatial deficits is reported to be characteristic of the

TABLE 5 Baseline Agreement^a between objective deficits and subjective reports according to close contacts in PD-MCI patients

Forgetting recent events		Forgetting remote events		Forgetting names		Forgetting appointments		Forgetting medications		Forgetting where objects are placed		
P value		P value		P value		P value		P value		P value		
(a) Memory questions												
Memory	0.064	.478	0.099	.302	-0.179	.061	0.101	.173	0.135	.093	0.095	.410
Attention	0.309	.018	-0.089	.274	0.274	.037	0.147	.219	-0.022	.863	0.01	.936
Executive	0.026	.599	-0.013	.809	-0.013	.809	0.045	.252	0.007	.863	-0.006	.936
Language	-0.053	.686	-0.199	.132	-0.199	.132	-0.132	.280	-0.152	.232	-0.165	.197
Visuospatial	-0.047	.438	0.020	.761	-0.133	.602	0.066	.162	0.030	.570	0.054	.518
Trouble sustaining attention												
		P value				P value				P value		P value
(b) Memory questions												
Memory	0.064	.478	-0.004	.964	-0.004	.964	-0.142	.076				
Attention	-0.068	.599	.387	.002	.387	.002	.387	.002				
Executive	-0.022	.659	0.007	.863	0.007	.863	0.007	.863				
Language	-0.185	.159	-0.152	.232	-0.152	.232	-0.152	.232				
Visuospatial	0.006	.927	0.030	.570	0.030	.570	-0.073	.164				
Trouble finishing tasks												
		P value				P value				P value		P value
(c) Executive function questions												
Memory	0.032	.669	0	NA	0	NA	-0.004	.964				
Attention	0.147	.219	0	NA	0	NA	0.251	.044				
Executive	0.045	.252	0	NA	0	NA	0.055	.205				
Language	-0.132	.28	0	NA	0	NA	-0.152	.232				
Visuospatial	-0.085	.073	0	NA	0	NA	-0.022	.680				
Trouble understanding												
		P value				P value				P value		P value
(d) Language questions												
Memory	0.029	.760	.363	0.067	-0.073	.363	0.068	.157				
Attention	0.153	.245	.357	-0.115	0.115	.357	-0.063	.481				
Executive	0.036	.498	.205	-0.01	0.055	.205	0.017	.481				
Language	0.053	.688	.232	-0.111	-0.152	.232	-0.062	.507				
Visuospatial	-0.086	.178	.122	0.003	0.081	.122	-0.023	.439				

(Continues)

TABLE 5 (Continued)

	Getting lost	P value	Finding multiple step activities confusing	P value	Dressing confusion	P value
(e) Non-verbal questions						
Memory	0	NR	-0.002	.971	0.034	.322
Attention	0	NR	0.034	.764	-0.033	.622
Executive	0	NR	-0.01	.764	0.009	.622
Language	0	NR	-0.111	.339	-0.032	.642
Visuospatial	0	NR	0.052	.215	0.013	.547

Note: NA: Not reported (no close contacts reported this problem). The threshold for statistical significance considering correction for multiple comparisons = a) Memory = 0.01, (b) attention = 0.017, (c) executive function = 0.017, (d) language = 0.0125, (e) non - verbal = 0.017. Statistically significant results are shown in bold type. Statistically significant results before multiple comparisons correction are shown in italics.

^aAgreement according to presence or absence of any complaint (kappa value).

typical cortical dysfunction that appears in the transition to dementia in PD.³⁵

Finally, regarding PD-CN subjects, we did not find any SCCs that predicted cognitive deterioration. Results may have been affected by sample size or the a priori decision to apply Bonferroni corrections, which some authors feel is too stringent.³⁶ If considering study results prior to application of the Bonferroni correction, patient-reported concerns regarding understanding and difficulty remembering medications could both predict cognitive deterioration in PD-CN individuals. It is plausible that these concerns may have particular value given that they had statistically significant associations with development of PDD when reported in individuals with PD-MCI.

The main limitation of the present study is the number of PD patients assessed. The number of patients who converted to PD-MCI or dementia at 1 and 2 years was similar to what has been previously reported³; however, considering that PD-MCI is a very heterogeneous entity, it is likely that we need a larger sample of PD-CN to predict different PD-MCI subtypes, and the relationships between SCCs and objective deficits may differ across subtypes. Unlike those individuals with amnesic MCI leading to dementia associated with AD neuropathology, PD-MCI shows more widespread, multidomain impairments while memory impairment does not always occur.^{3,37} This heterogeneity may underlie different pathophysiological substrates. Even though the subtypes of cognitive impairment in PD are not well defined yet, the longitudinal CamPaIGN study in provides a strong argument for this. Persons with PD without dementia were classified as a frontostriatal/executive or posterior cortical (language and visuospatial deficits) dysfunction profile, the latter predicted dementia within 5 years of PD diagnosis.³⁸ Of note, cognitive functions and subjective memory complaints in PD patients can be affected by presence of depression. However, our study excluded patients with significant depression at baseline.^{39,40}

The main strength of our work is that we assessed presence of SCCs not only in the memory realm but also within the other main cognitive domains (ie, attention, executive function, language, and non-verbal cognitive functions). The importance of the evaluation of specific cognitive complaints is that they are not only related to memory and reflect new subjective difficulties that may herald dementia in PD. This is an easy assessment that could be considered to be included in the formal neuropsychological assessment. Also, as opposed to some other studies that applied level I MDS criteria for PD-MCI diagnosis⁸⁻¹⁰ we applied level II criteria that seem to be more accurate since they include a comprehensive neuropsychological assessment evaluating the five cognitive domains.¹⁶

We can conclude that eliciting SCCs from both patients and contacts that assess different domains is crucial for a complete evaluation of cognition in PD. Our findings suggest that whereas patients' complaints related to inattention may predict progression to dementia in PD-MCI, they might not be aware of deficits in memory and language reported by their CC. In this regard, forgetting medications and difficulties understanding seem to be associated with the emergence of dementia in the short term. Therefore, we

conclude that eliciting cognitive complaints, including all cognitive domains and not only memory, may help to predict cognitive outcome. This is an easy and short evaluation that should be administered to both patient and CC. These results require replication with a larger sample allowing investigation of these relationships within subtypes of PD-MCI.

ACKNOWLEDGMENTS

We acknowledge the patients for their collaboration in the study.

CONFLICT OF INTEREST

The authors report no conflict of interest regarding the study.

DATA AVAILABILITY STATEMENT

Data of this work are available upon reasonable request to the corresponding author.

ORCID

Carmen Gasca-Salas  <https://orcid.org/0000-0001-7411-8106>

REFERENCES

- Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson's disease: A multicenter pooled analysis. *Neurology*. 2010;75:1062-1069.
- Hoogland J, Boel JA, Bie RMA, et al. Risk of Parkinson's disease dementia related to level I MDS PD-MCI. *Mov Disord*. 2019;34:430-435.
- Saredakis D, Collins-Praino LE, Gutteridge DS, Stephan BCM, Keage HAD. Conversion to MCI and dementia in Parkinson's disease: a systematic review and meta-analysis. *Parkinsonism Relat Disord*. 2019;65:20-31.
- Lehrner J, Moser D, Klug S, et al. Subjective memory complaints, depressive symptoms and cognition in Parkinson's disease patients. *Eur J Neurol*. 2014;21:1276-1277.
- Rami L, Fortea J, Bosch B, et al. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. *J Alzheimer's Dis*. 2011;23:319-326.
- Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. *Lancet Neurol*. 2009;8:619-627.
- Scheef L, Spottke A, Daerr M, et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. *Neurology*. 2012;79:1332-1339.
- Erro R, Santangelo G, Barone P, et al. Do Subjective Memory Complaints Herald the Onset of Mild Cognitive Impairment in Parkinson Disease? *J Geriatr Psychiatry Neurol*. 2014;27:276-281.
- Hong JY, Sunwoo MK, Chung SJ, et al. Subjective cognitive decline predicts future deterioration in cognitively normal patients with Parkinson's disease. *Neurobiol Aging*. 2014;35:1739-1743.
- Galtier I, Nieto A, Lorenzo JN, Barroso J. Subjective cognitive decline and progression to dementia in Parkinson's disease: a long-term follow-up study. *J Neurol*. 2019;266:745-754.
- Aldakheel A, Gasca-Salas C, Armstrong MJ, Duff-Canning S, Marras C. Marras C Cognitive Complaints in Nondemented Parkinson's Disease Patients and Their Close Contacts do not Predict Worse Cognitive Outcome. *Alzheimer Dis Assoc Disord*. 2019;33:147-153.
- Copeland JN, Lieberman A, Oravivattanakul S, Tröster AI. Accuracy of Patient and Care Partner Identification of Cognitive Impairments in Parkinson's Disease-Mild Cognitive Impairment. *Mov Disord*. 2016;31:693-698.
- Marras C, Armstrong MJ, Meaney CA, et al. Measuring mild cognitive impairment in patients with Parkinson's disease. *Mov Disord*. 2013;28:626-633.
- Armstrong MJ, Naglie G, Duff-Canning S, et al. Roles of Education and IQ in Cognitive Reserve in Parkinson's Disease-Mild Cognitive Impairment. *Dement Geriatr Cogn Dis Extra*. 2012;2:343-352.
- Gélinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia. *Am J Occup Ther*. 1999;53:471-481.
- Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. *Mov Disord*. 2012;27:349-356.
- Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia. Clinical diagnostic criteria for dementia associated with Parkinson's disease. *Mov Disord*. 2006;22:1689-1707.
- Delis DC, Kaplan E, Kramer J. Examiner's Manual for the Delis-Kaplan Executive Function System. *Child Neuropsychol*. 2001;10:301-303.
- Wechsler D. Wechsler Memory Scale- (Fourth Ed.). The Psychological Corporation. 2010.
- Goldman JG, Holden S, Ouyang B, Bernard B, Goetz CG, Stebbins GT. Diagnosing PD-MCI by MDS task force criteria: How many and which neuropsychological tests? *Mov Disord*. 2015;30:402-406.
- Kaplan E, Goodglass H, Weintraub S. *The Boston naming test*. Philadelphia, PA: Lea & Febiger; 1983.
- Williams BW, Mack W, Henderson VW. Boston naming test in Alzheimer's disease. *Neuropsychologia*. 1989;27(8):1073-1079.
- Carone DAE, Strauss EMS, Sherman O, Spreen A. Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. *Appl Neuropsychol*. 2010.
- Meyers JE, Meyers KR. Rey Complex Figure Test and recognition trial. *Psychological Assessment Resources*. 1995.
- Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test – second edition. Adult version. Manual Test. 2000.
- Benton AL, Sivan AB, Hamsher KDS, Varney NR, Spreen O. *Contributions to Neuropsychological Assessment: A Clinical Manual*. Oxford: Oxford University Press; 1994.
- Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data. *Biometrics*. 1977;33(1):159-174.
- Hanagasi HA, Tufekcioglu Z, Emre M. Journal of the Neurological Sciences Dementia in Parkinson's disease. *J Neurol Sci*. 2017;374:26-31.
- Smith KM, Caplan DN. Brain and Language Communication impairment in Parkinson's disease: Impact of motor and cognitive symptoms on speech and language. *Brain Lang*. 2018;185:38-46.
- Kudlicka A, Clare L, Hindle JV. Awareness of Executive Deficits in People with Parkinson's Disease. *J Int Neuropsychol Soc*. 2013;19(5):559-570.
- Donata M, Assogna F, Pellicano C, et al. Parkinsonism and Related Disorders Anosognosia for cognitive and behavioral symptoms in Parkinson's disease with mild dementia and mild cognitive impairment: Frequency and neuropsychological / neuropsychiatric correlates. *Park Relat Disord*. 2018;54:62-67.
- Reginold W, Armstrong MJ, Duff-Canning S, et al. The pill questionnaire in a nondemented Parkinson's disease population. *Mov Disord*. 2012;27:1308-1311.
- Christ JBM, Fruhmann M, Riedl E, et al. Parkinsonism and Related Disorders How precise are activities of daily living scales for the diagnosis of Parkinson's disease dementia? A pilot study. *Park Relat Disord*. 2013;19:371-374.

34. Lee W-J, Chang Y-Y, Lin J-J, et al. Comparison of activities of daily living impairments in Parkinson's disease patients as defined by the Pill Questionnaire and assessments by neurologists. *J Neurol Neurosurg Psychiatr*. 2014;85(9):969-973.
35. Pagonabarraga J, Kulisevsky J, Llebaria G, Pascual-sedano B, Gironell A, Garcı C. Parkinson ' s Disease-Cognitive Rating Scale : A New Cognitive Scale Specific for Parkinson ' s Disease. *Mov Disord*. 2008;23:998-1005.
36. Bonferroni CE. The Concise Encyclopedia of Statistics [Internet]. New York, NY: Springer, New York; 2008. p. 50–51.
37. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson ' s disease. *Lancet Neurol*. 2010;9:1200-1213.
38. Williams-gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson ' s disease: 5 year follow-up of the CamPaIGN cohort. *Brain*. 2009;132:2958-2969.
39. Santangelo G, Vitale C, Trojano L, et al. Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia. *J Neurol*. 2009;256:632-663.
40. Santangelo G, Vitale C, Trojano L, et al. Subthreshold depression and subjective cognitive complaints in Parkinson's disease. *Eur J Neurol*. 2014;21:541-544.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Gasca-Salas C, Duff-Canning S, Armstrong MJ, et al. Parkinson disease with mild cognitive impairment: Domain-specific cognitive complaints predict dementia. *Acta Neurol Scand*. 2020;142:585–596. <https://doi.org/10.1111/ane.13326>